Abstract: Alpha-lipoic acid (LA), a naturally occurring dithiol compound, is an essential cofactor in metabolic reactions involved in energy utilization. LA improves glycemic control, reduces diabetic polyneuropathies, atherosclerosis, and allergic inflammation. The effects of LA on mast cell-mediated anaphylactic reactions, however, are unknown. LA dose-dependently inhibited systemic and passive cutaneous anaphylaxis-like reactions in mice induced by compound 48/80, a condensation product of N-methyl-p-methoxyphenethylamine and formaldehyde. Pretreatment with LA, prior to induction of the systemic anaphylaxis-like reaction with compound 48/80, reduced plasma histamine levels in a dose-dependent manner. In our in vitro study, LA decreased histamine release from rat peritoneal mast cells (RPMCs) triggered by compound 48/80. Moreover, an increase in calcium uptake activated by compound 48/80 was inhibited by LA. LA also significantly elevated intracellular cyclic adenosine-3',5' monophosphate (cAMP) levels in RPMCs. This inhibition of mediator release from RPMCs may be due to inhibition of calcium uptake and augmentation of intracellular cAMP levels. Based on these results, we suggest that LA may be a potential remedy for allergy-related diseases.
Introduction
Mast cells are bone marrow-derived effector cells of the immune system, found abundantly in connective tissue, skin, mucosal membranes, and tissues which interface with the external environment. It has been thought that mast cells play a major role in the development of many physiological changes during allergic responses. Mast cell activation by both IgE-dependent and IgE-independent stimuli initiate degranulation which results in the fusion of cytoplasmic granule membranes with plasma membranes. This process is accompanied by the fast external release of granule-associated www.acbjournal.com www.acbjournal.org doi: 10.5115/acb.2010.43.4.317 a good experimental model for the study of compound 48/80-induced histamine release and anaphylaxis-like reactions.
Alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid; LA), a disulphide derivative of octanoic acid, is known to act as an efficient anti-oxidant and metal-chelating agent (Shay et al., 2009) . LA has been used to treat many diseases including diabetic complications, polyneuropathies, atherosclerosis, diseases of joints, and acquired immune deficiency syndrome (Bilska & Wlodek, 2005) . LA has also been considered as a therapeutic agent candidate for the treatment or prevention of pathologies associated with an imbalance of oxidoreductive status, such as neurodegeneration, ischemia-reperfusion, hepatic disorders, and asthma (Shay et al., 2009) . Recent studies have revealed that LA effectively suppresses allergic inflammation in a murine model of asthma by reducing the level of reactive oxygen species (Cho et al., 2004) . However, the effects of LA on mast cell-mediated allergic inflammation and cellular regulation remain unknown.
In this study, we aimed to investigate the effect of LA on mast cell-mediated immediate-type hypersensitivity. The results clearly demonstrated that LA displays anti-allergic activity in both in vivo and in vitro models.
Materials and Methods

Materials
Lipoic acid (LA; Thioctacid 600) was obtained from VIATRIS GmbH & CoKG (Frankfurt, Germany) . Compound 48/80, bovine serum albumin (BSA), disodium cromoglycate (DSCG) and HEPES were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Percoll solution was purchased from Pharmacia (Uppsala, Sweden). LA and compound 48/80 were freshly diluted in phosphate buffered saline (PBS) for all in vitro experiments.
Experimental animals
Male ICR mice and Sprague Dawley rats were purchased from Damool Science (Daejeon, Korea). Animals were housed 3~5 per cage in laminar air-flow cabinets maintained at 22±1 o C and a relative humidity of 55±10% throughout the study. All experiments were performed in compliance with the guidelines approved by the Institutional Animal Care and Use Committee of the Chonbuk National University Medical School.
Compound 48/80-induced systemic anaphylaxis-like reactions in mice
Mice (n=10/group) received an intraperitoneal injection of compound 48/80 (8 mg/kg body weight [BW]) as described previously (Choi et al., 2006) . LA (10, 50, 100 mg/kg BW) was diluted in PBS and administered orally at 24, 12, and 1 h prior to compound 48/80 administration. Mortality was monitored for 1 h after induction of anaphylactic shock. At the conclusion of the mortality test, blood was obtained by cardiac puncture.
Preparation of plasma and histamine determination
The blood was centrifuged at 150×g for 10 min at 4 o C and histamine content was measured by radioenzymatic method from the plasma (Carvalho et al., 2010) .
Compound 48/80-induced a passive cutaneous anaphylaxis (PCA)-like reaction
After intradermal injection of 0.5 μg/20 μl of compound 48/80 to the dorsal skin of each mouse, 2% Evans blue solution was intravenously injected into the lateral tail vein. LA was administered orally 24, 12, and 1 h before the injection of compound 48/80. As a control, a mast cell-stabilizing agent, DSCG, was given orally 24, 12, and 1 h prior to the injection of compound 48/80. Mice were euthanized with a terminal anesthesia dose 30 min after the 2% Evans blue injection. Tissue sections around the intradermal injection site were excised and weighed. Extravasated Evans blue dye was extracted by incubation of biopsies in 1 ml formamide at 55 o C for 24 h. Absorbance was measured at 620 nm using a spectrophotometer (Spectra MAX PLUS, Molecular Devices, CA, USA). Tissue Evans blue concentrations were quantified by interpolation on a standard curve of dye concentrations in the range of 0.01 to 30 μg/ml.
Preparation of mast cell suspensions and microscopic observation
RPMCs were isolated as follows: rats were anesthetized with ether and injected with 10 ml of calcium-free HEPESTyrode's buffer (136 mM NaCl, 5 mM KCl, 11 mM NaHCO 3 , 0.6 mM NaH 2 PO 4 , 5.4 mM HEPES, 1.0 mg/ml glucose) into the peritoneal cavity, and the abdomen gently massaged for about 90 s after which the peritoneal cavity was opened and the fluid aspirated using a Pasteur pipette. RPMCs were purified using a Percoll density gradient as described in detail elsewhere (Martynova et al., 2005 at least 95% pure as assessed by toluidine blue staining and at least 98% of these cells were viable according to trypan blue exclusion. Purified mast cells (1×10 6 cells/ml) were resuspended in HEPES-Tyrode's buffer (136 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 11 mM NaHCO 3 , 0.6 mM NaH 2 PO 4 , 2.75 mM MgCl 2 , 5.4 mM HEPES, 1.0 mg/ml BSA, 1.0 mg/ml glucose, 0.1 mg/ml heparin, pH 7.4), observed under a phase contrast microscope and photographed.
Mast cell viability assay
To test the viability of cells, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was performed as described previously (Yoshimura et al., 2004) . Briefly, RPMCs (1×10 6 cells/well) were incubated with various concentrations (1~4 mM) of LA at 37 o C for 2 h. After addition of MTT (100 μg in 100 μl saline) cells were incubated at 37 o C for 1 h. The crystallized MTT was dissolved and absorbance measured at 570 nm with a spectrophotometer.
Histamine release assay
Mast cell suspensions (2×10 5 cells in 200 μl) were preincubated with LA (1~4 mM) at 37 o C for 10 min and then incubated with compound 48/80 (0.25 μg/ml) for 10 min. Following centrifugation at 150×g for 10 min, the amount of histamine in the supernatant was determined by the radioenzymatic method (Carvalho et al., 2010) . The inhibition percentage of histamine release was calculated using the following formula: 
Measurement of cyclic adenosine-3',5' monophosphate (cAMP) levels
Mast cell suspensions were added to an equivalent volume (200 μl) of prewarmed buffer containing LA (1~4 mM) in Eppendorf tubes. The reaction was allowed to proceed for specific time intervals, terminated by centrifugation. Each sample was then added to 250 μl of 50 mM sodium acetate buffer (pH 6.2) under vigorous vortexing, followed by snap freezing in liquid nitrogen. Frozen samples were thawed and vortexed, and the debris sedimented by centrifugation 1,200×g at 4 o C for 10 min. The cAMP levels in the supernatants were determined with cAMP radioimmunoassay kits (PerkinElmer Life Sciences).
Statistical analysis
The results obtained are expressed as mean±standard error of the mean (SEM). Statistical evaluation of the results was performed using one-way ANOVA, followed by Duncan's multiple range tests. Results with P<0.05 were considered statistically significant.
Results
Effect of LA on compound 48/80-induced systemic anaphylaxis-like reactions
To investigate the effect of LA on anaphylaxis-like reactions, we first used a mouse in vivo model with compound 48/80. After intraperitoneal injection of compound 48/80 (8 mg/kg BW) the mortality rate was examined for 1 h. As shown in Table 1 , injection of compound 48/80 resulted in 100% death. Oral administration of LA (10, 50, 100 mg/ kg BW) reduced compound 48/80-induced mortality in a dose-dependent manner. DSCG (reference drug) also dosedependently inhibited compound 48/80-induced mortality.
Effect of LA on compound 48/80-induced plasma histamine release
LA was given at doses ranging from 10 to 100 mg/kg BW at 24, 12, and 1 h prior to injection of compound 48/80. Oral administration of LA reduced the plasma histamine release induced by compound 48/80 in a dose-dependent manner (Table 2 ). In addition, the reference drug DSCG attenuated www.acbjournal.com www.acbjournal.org 
Effect of LA on compound 48/80-induced PCA-like reactions
It has been previously demonstrated that intradermal injection of compound 48/80 into the dorsal skin of mice provokes the increase of mast cell-dependent vascular permeability (Shinmei et al., 2004) . As shown in Table 3 , oral administration of LA dose-dependently reduced the vascular permeability changes induced by compound 48/80. Likewise, DSCG significantly inhibited the PCA-like reaction triggered by compound 48/80 at a dose of 100 mg/kg BW.
Effect of LA on mast cell viability
An MTT conversion assay was used to determine the viability of RPMCs exposed to LA. Cell viability was almost 100% after exposure to 4 mM LA for 2 h (Fig. 1) ; thus, LA had no cytotoxic effects on RPMCs.
Effect of LA on mast cell degranulation of RPMCs
To investigate the inhibitor y mechanism of LA on anaphylactic reactions, we examined compound 48/80-induced mast cell activation (Fig. 2) . Control RPMCs were generally spherical or oval in shape and contained many fine granules surrounding a prominent nucleus ( Fig. 2A) . Following stimulation with compound 48/80 for 10 min, RPMCs showed characteristics of mast cell degranulation Groups of mice (n=10/group) were orally administered with 300 μl of PBS or drugs {LA or disodium cromoglycate (DSCG)} at 24, 12 and 1 h before the injection of compound 48/80. The compound 48/80 solution was intraperitoneally given to the group of mice. Mortality (%) within 1 h following compound 48/80 injection was presented as the number of dead mice ×100/ total number of experimental mice. *PBS, phosphate-buffered saline. with cell swelling, cytoplasmic vacuoles, and extruded granules near the cell surface and in the surrounding medium (Fig. 2B) . When RPMCs were incubated with LA alone they appeared similar to control cells (Fig. 2C) . Pretreatment with LA inhibited degranulation of RPMCs induced by compound 48/80. The cell sizes were somewhat larger than the control cells (Fig. 2D) ; however, there was no statistical significant difference in size between the two groups (data not shown). These results suggest that LA suppresses compound 48/80-induced mast cell degranulation.
Effect of LA on histamine release from RPMCs
Histamine release from compound 48/80-treated RPMCs was reduced in a dose-dependent manner by LA (Fig. 3) . DSCG also suppressed compound 48/80-induced histamine release. These results indicate that LA inhibits the compound 48/80-induced anaphylactic-like reaction by blocking histamine release from RPMCs.
Effect of LA on calcium uptake into RPMCs
Calcium plays an important role in the stimulus-secretion coupling of mast cells. It is also well established that an increase in calcium uptake into RPMCs contributes to the release of histamine (Akagi et al., 1994) . Therefore, we measured calcium uptake and found that treatment with LA had no effect on calcium uptake. However, calcium uptake was substantially increased by stimulation of RPMCs with compound 48/80. This compound 48/80-elicited calcium uptake response was inhibited by LA in a concentrationdependent manner (Fig. 4) . At a concentration of 4 mM of LA, calcium uptake was nearly completely blocked. These results suggest that LA may inhibit mediator release by blocking calcium uptake into RPMCs. 
Effect of LA on cAMP levels of RPMCs
Earlier findings have shown that the cAMP pathway participates in the modulation of mast cell activation. Increased cAMP is known to precede the prevention of mediator release from mast cells activated by compound 48/80 or IgE (Tasaka et al., 1986) . To investigate the mechanism of LA involved in the reduction of mediator release from RPMCs stimulated by compound 48/80, we assessed intracellular cAMP levels. The level of cAMP was not changed in unstimulated RPMCs. Treatment of RPMCs with LA resulted in an increase in cAMP in a concentration-dependent manner. When RPMCs were incubated with 2 or 4 mM LA, the cAMP level was rapidly increased within 1 min and decreased to the basal level after 3 min (Fig. 5) . These results suggest that LA may suppress mediator release by increasing the cAMP level in RPMCs.
Discussion
The present study has demonstrated that LA inhibits compound 48/80-induced systemic anaphylaxis-like and passive cutaneous anaphylaxis-like reactions in mice. Pretreatment with the same concentration of LA before the systemic anaphylaxis-like reaction also reduces the plasma histamine content in a dose-dependent manner. To further examine the mechanism by which LA attenuates mast cellmediated anaphylactoid reactions, we examined compound 48/80-induced mast cell activation. Compound 48/80-induced histamine release from RPMCs was blocked by treatment with LA. Compound 48/80 is well-known to induce mast celldependent, non-specific anaphylactic reactions. Additionally, it is widely accepted that the mechanism involved in the anaphylaxis-like response activated by compound 48/80 is due to the massive release of histamine from mast cells and basophils (Nishikawa & Kitani, 2008) . Therefore, these results suggest that LA could inhibit the mast cell-derived anaphylactoid reactions by preventing histamine release from RPMCs triggered by compound 48/80.
Several reports have shown that compound 48/80 increases the permeability of the lipid bilayer membrane of mast cells by causing perturbation of the membrane (Tasaka et al., 1986) . These findings indicate that the increase in cell membrane permeability may be an essential trigger for the release of mediators from mast cells. Thus, it is reasonable to presume that LA might inhibit histamine release by attenuating the permeability of RPMC membranes by preventing compound 48/80-induced membrane perturbation. However, we found no evidence in our study to substantiate this assumption. In order to reveal the mechanisms involved in histamine release inhibition by LA, additional research is required.
To further examine the mechanisms by which LA inhibits mast cell-dependent anaphylaxis-like reactions, we chose to study two different signal transduction steps, namely calcium influx and cAMP production in mast cells. It is well-recognized that agents that elevate cAMP are effective 
